The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib
Open accessAbstract
PURPOSE: BIM is essential for the response to tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) patients. Recently, a deletion polymorphism in intron 2 of the BIM gene was demonstrated to confer an intrinsic TKI resistance in Asian patients. The present study aimed at identifying mutations in the BIM sequence that could lead to imatinib resistance independently of BCR-ABL mutations. EXPERIMENTAL DESIGN: BIM coding sequence analysis was performed in 72 imatinib-treated CML patients from a French population of our centre and in 29 healthy controls (reference population) as a case-control study. Real-time quantitative PCR (RT qPCR) was performed to assess Bim expression in our reference population. RESULTS: No mutation with amino-acid change was found in the BIM coding sequence. However, we observed a silent single nucleotide polymorphism (SNP) c465C>T (rs724710). A strong statistical link was found between the presence of the T allele and the high Sokal risk group (p = 0.0065). T allele frequency was higher in non responsive patients than in the reference population (p = 0.0049). Similarly, this T allele was associated with the mutation frequency on the tyrosine kinase domain of BCR-ABL (p<0.001) and the presence of the T allele significantly lengthened the time to achieve a major molecular response (MMR). Finally, the presence of the T allele was related to a decreased basal expression of the Bim mRNA in the circulating mononuclear cells of healthy controls. CONCLUSION: These results suggest that the analysis of the c465C>T SNP of BIM could be useful for predicting the outcome of imatinib-treated CML patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Responsiveness to anti-VEGF, corticosteroids, and tyrosine kinase inhibitors hinge on BIM function, with BIM polymorphisms negating effective treatment [27, 33, 39].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The synonymous BIM polymorphism (rs724710) has a CC allele frequency that varies from 43–87% depending on the population background [28, 33, 40]”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“with higher basal BIM expression reported in individuals having this CC allele [27, 33].”
From Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients (2024) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
SNPStats: a web tool for the analysis of association studies
Solé, X., Guinó, E., Valls, J., Iniesta, R., & Moreno, V. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl268 · Cited by 2,006
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,228
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
Duan, J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/12.3.205 · Cited by 930
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
Self-citationNg, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
Bim is a suppressor of Myc-induced mouse B cell leukemia
Egle, A., Harris, A. W., Bouillet, P., & Cory, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401471101 · Cited by 488
Research works printed but not linked: 2
- International HapMap project website. Available http://hapmap.ncbi.nlm.nih.gov/ Accessed 2008
- dbSNP website. Available http://www.ncbi.nlm.nih.gov/SNP/. Accessed 2008
Cited by
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Tanimoto, A., Takeuchi, S., Arai, S., Fukuda, K., Yamada, T., Roca, X., Ong, S. T., & Yano, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2271 · Cited by 101
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia
Awad, S. A., Kankainen, M., & Mustjoki, S. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894652 · Cited by 42
Zhang, A., Yu, J., Yan, S., Zhao, X., Chen, C., Zhou, Y. Y., Zhao, X., Hua, M., Wang, R., Zhang, C., et al. (2017) · Human Immunology · doi:10.1016/j.humimm.2017.10.013 · Cited by 39
Differential Impacts of Alternative Splicing Networks on Apoptosis
Lin, J.-C., Tsao, M.-F., & Lin, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122097 · Cited by 41
Metadata
- Authors
- Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Augis, Vanessa
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-11-05
- Volume
- 8
- Issue
- 11
- Pages
- e78582
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3818406
- OpenAlex
- W2079281117
- Cited by
- 35
- References
- 25
- Citations by year
- 2026: 3 · 2024: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 4
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ligue Contre le Cancer
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- chronic myeloid leukemia, imatinib, single nucleotide polymorphisms, major molecular response, imatinib resistance, BCR-ABL mutations, tyrosine kinase inhibitors, prognostic factors
- MeSH terms
- Imatinib Mesylate, Bcl-2-Like Protein 11, Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Benzamides, Child, Child, Preschool, Female, Gene Frequency, Humans, Leukocytes, Mononuclear, Male, Membrane Proteins, Middle Aged, Piperazines, Proto-Oncogene Proteins, Pyrimidines, RNA, Messenger, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gene Expression, Case-Control Studies, Fusion Proteins, bcr-abl, Polymorphism, Single Nucleotide, Apoptosis Regulatory Proteins, Biomarkers, Pharmacological, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib. https://app.cochat.ai/papers/10.1371/journal.pone.0078582
- The paper
- Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F. (2013). A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib. PLoS ONE. https://doi.org/10.1371/journal.pone.0078582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.